Search Results

search

Search Filters

Organization
Phathom Pharmaceuticals
Phathom_Pharm_Logo.jpg
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 06, 2025 08:00 ET | Phathom Pharmaceuticals
VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled...
Phathom_Pharm_Logo.jpg
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
February 24, 2025 08:00 ET | Phathom Pharmaceuticals
Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...
Phathom_Pharm_Logo.jpg
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom_Pharm_Logo.jpg
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
December 11, 2024 08:00 ET | Phathom Pharmaceuticals
Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom believes applicable law mandates a 10-year...
Phathom_Pharm_Logo.jpg
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 07, 2024 08:00 ET | Phathom Pharmaceuticals
Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increaseOver 143,000 prescriptions filled for...
phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
November 04, 2024 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
October 28, 2024 08:00 ET | Phathom Pharmaceuticals
Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
October 27, 2024 12:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
August 29, 2024 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
August 19, 2024 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...